– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma – NEW HAVEN, Conn., June 05, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targete ...

Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS.Study results suggest inFoods IBS could be particularly beneficial for IBS-M patients, a population with no current FDA-approved drug treatments. IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (N ...

Worksport Ltd Figure 1: Closeups of the Worksport SOLIS & COR Nano-Grid Company Projects Millions in New 2025 Revenues. Modular Nano-Grid System Delivers 4,000Wh+ of Solar Generated Energy; Targeting Vehicles, Jobsites, Military, and Portable Power Markets. West Seneca, New York, June 05, 2025 (GLOBE NEWSWIRE) -- Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a U.S. based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer ...

CORNELIUS, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (NASDAQ: AMOD), a leader in AI-driven retail technology and real-time consumer intelligence, today announced the appointment of Tim Matthews as Head of Deployment Strategy. Matthews, a seasoned marketing executive with deep experience in fintech and digital product launches, joins Alpha Modus at a pivotal time in its national CashX kiosk expansion. Matthews will be responsible for spearheading the rollout of Alpha Modus’s proprie ...

Core Insights - IREN Limited reported record monthly revenue and hardware profit for May 2025, driven by increased Bitcoin prices and a rise in average operating hashrate [5][6][11] - The company is on track to achieve a hashrate of 50 EH/s by June 30, 2025, with ongoing customer engagement and financing workstreams [5][11] - AI Cloud Services revenue is continuing to scale, with the Horizon 1 AI Data Center project on schedule for delivery in Q4 2025 [5][7] Bitcoin Mining Performance - Average operating hashrate increased to 38.4 EH/s in May from 36.6 EH/s in April and 30.3 EH/s in March [4] - Bitcoin mined reached 627 BTC in May, up from 579 BTC in April and 533 BTC in March [4] - Revenue per Bitcoin increased to $103,345 in May from $86,522 in April [4] - Total revenue from Bitcoin mining was $64.7 million in May, compared to $50.1 million in April [4] - Electricity costs per Bitcoin rose to $27,033 in May from $24,381 in April [4] - Hardware profit for Bitcoin mining was $47.8 million in May, with a profit margin of 74% [4][11] AI Cloud Services - Revenue from AI Cloud Services was $2.2 million in May, up from $2.0 million in April [4] - Hardware profit margin for AI Cloud Services remained high at 98% in May [4] - The GPU fleet is nearing full utilization, supporting training and inference workloads, generating an annualized run-rate revenue of $28 million [11] Project Updates - The Childress project is progressing, with Phase 5 (150MW) energization expected in the coming weeks [10][14] - The Horizon 1 AI Data Center is on track for Q4 2025 delivery, with equipment arriving as planned [7][14] - The company is transitioning to US domestic issuer status starting July 1, 2025 [5]

Company Overview - ZJK Industrial Co., Ltd. is a high-tech precision parts and hardware manufacturer focused on sectors such as artificial intelligence infrastructure, consumer electronics, electric vehicles, and aerospace [4] - The company specializes in manufacturing precision fasteners, structural parts, and other precision metal components, with a strong emphasis on innovation and manufacturing excellence [4] Market Development - ZJK is ramping up production to meet the increasing demand from Nvidia's B40 project, which is a customized AI accelerator targeting the Chinese market [1][2] - The B40 chip is based on Nvidia's Blackwell architecture and aims at the mid-to-high-end market segment, with mass production expected to start as early as June 2025 [2] Growth Potential - The CEO of ZJK highlighted that the B40 project presents significant market advantages and is expected to complement Nvidia's RTX Pro 6000 workstation graphics cards [3] - Supply chain forecasts predict that B40 chip shipments could exceed one million units by the end of 2025, indicating substantial growth potential for ZJK as a supplier to Nvidia [3] - The company anticipates significant year-over-year revenue growth from this initiative, driven by the expanding AI sector [3]

Company Overview - NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C) [1][5] - The company aims to address the unmet need for safe, well-tolerated, and convenient LDL-lowering therapies, particularly for patients who do not respond adequately to existing treatments [5] R&D Day Announcement - NewAmsterdam will host an R&D Day event for analysts and investors on June 11, 2025, at 9:00 a.m. ET in New York City [1] - The event will feature key members of the management team, including the CEO and Chief Scientific Officer [2] Obicetrapib Development - Obicetrapib is a novel, oral, low-dose CETP inhibitor being developed by NewAmsterdam to improve LDL-lowering treatment outcomes [4] - The company has conducted multiple Phase 2 and Phase 3 trials, demonstrating statistically significant LDL-lowering effects with a side effect profile similar to placebo [4] - The Phase 3 PREVAIL CVOT trial, which commenced in March 2022, has enrolled over 9,500 patients to assess obicetrapib's potential in reducing major adverse cardiovascular events (MACE) [4] Commercialization Rights - The commercialization rights for obicetrapib in Europe have been exclusively granted to the Menarini Group, a leading international pharmaceutical and diagnostics company [4]

NANO Nuclear Energy Inc. Figure 1 - NANO Nuclear Energy Appoints Former U.S. Department of Energy (DOE) Leader and Technology Executive Dr. Seth Berl to its Board of Directors. New York, N.Y., June 05, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that its Board of Directors has appointed prominent technology executive Seth Berl, Ph.D ...

Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the release of its Soft Tissue Sarcoma (STS) Lung Mets KOL Webcast discussing the final data from its U.S. Phase 1B/2 clinical trial evaluating Annamycin as monotherapy for the treatment of soft tissue sarcoma lung metastase ...

LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of Imunon, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, June 12, 2025, at 11:30 a.m. ET. Pre-register for Imunon’s virtual presentation at the Virtual Investor Conferences site HERE. This will be a live, interactive online eve ...